New once-daily pill may improve kidney transplant outcomes
NCT ID NCT03321656
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a once-daily anti-rejection drug (Envarsus XR) to the standard twice-daily drug in 78 adults receiving a kidney transplant. The goal is to see if the once-daily option reduces hidden rejection and improves immune system markers. Participants will be followed for changes in donor-specific antibodies and kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Deepa Valvi
RECRUITINGLexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test